Skip to main content
Equibles
EVAX logo

EVAX · Evaxion A/S

Track EVAX — free

Use EVAX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about EVAX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.34 +0.13 (+4.02%) At close · Aug 14
Market Cap
$27.86M
Shares
8.34M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.34 Open$3.29 Day$3.16–3.34 52W close$2.59–11.01 Avg vol 30d14K Short int17K · 0.2% float · 1.4d Short vol25% Last earningsAug 20, 2026 DataJan 2025–Aug 2026

Raw chart and full-history price indicators begin at the captured split on Jan 14, 2025; bars on opposite sides are not compared.

Up next

Next earnings call
Aug 20, 2026 Scheduled · this week
FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −19%
below
Price vs 50-day avg +4%
above
RSI (14) 64
neutral
MACD trend Positive
52-week position 9%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +9%
trailing
6-month return +3%
trailing
YTD return −30%
this year
Relative strength −11%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+18% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.20% of float · ▼ -19.5% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
20 holders — near 3-yr high, broad support
Squeeze score 33
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 113%
annualized · 1-yr
Max drawdown −75%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 31, 2026
Operational cash burn · 2026 $14M
Prior guidance period ended · from the Earnings Call filed Dec 31, 2023
2024 operational cash burn · FY2024 up to $14M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−19% Bearish
Price vs 50-day avg
+4% Bullish
RSI (14)
64 Neutral
MACD trend
Positive Bullish
52-week position
9% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+18% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.20% of float · ▼ -19.5% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
20 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $3 · 9% Range high $11
vs 200-day avg -19% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EVAX
Evaxion A/S
this stock
$27.86M -30.0% — — 0.2%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
20
% held
19.1%
Net QoQ
+49.5K sh
Top holder
Merck & Co., Inc.
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Falling
Shares short
16.8K
Days to cover
1.4d
Change
-4.1K sh
View
Short Volume
Short vol %
25%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
20
Value
$82
As of
May 19, 2026
View
Off-Exchange
Off-exchange %
56.3%
Week of
Jul 6, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 14, 2026
This year
26
View
Earnings & Events
Earnings Calls Upcoming
Next call
Aug 20, 2026
Last call
Mar 31, 2026
View
Investor Relations
Upcoming events
2
View

Performance

Raw-price comparisons begin at the captured split on Jan 14, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
EVAX +7.7% +8.6% +3.1% +18.4% -30.0%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +7.3% +4.2% -10.7% +14.5% -43.8%
Key facts CIK 1828253 CUSIP 29970R303 13F (30d) 19 filings 19 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)